Last reviewed · How we verify
Tranexamic Acid (Intravenous)
Tranexamic acid inhibits the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.
Tranexamic acid inhibits the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability. Used for Reduction of blood loss during surgical procedures, Trauma-associated hemorrhage, Perioperative bleeding prevention.
At a glance
| Generic name | Tranexamic Acid (Intravenous) |
|---|---|
| Also known as | trans-4-(aminomethyl)cyclohexanecarboxylic acid, Cyklokapron |
| Sponsor | The New England Baptist Hospital |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits plasminogen activation and plasmin activity. By reducing the breakdown of fibrin clots, it helps maintain hemostasis and reduce bleeding. It is commonly used to reduce blood loss during surgery and in trauma settings.
Approved indications
- Reduction of blood loss during surgical procedures
- Trauma-associated hemorrhage
- Perioperative bleeding prevention
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Seizures
- Visual disturbances
- Nausea
- Hypotension
Key clinical trials
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH (PHASE3)
- Tranexamic Acid for Bleeding Reduction During TURP Surgery (PHASE4)
- Epinephrine-Added Irrigation Versus Intravenous Tranexamic Acid in Arthroscopic Rotator Cuff Repair: A Prospective Randomized Controlled Trial (NA)
- One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures (NA)
- The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients (PHASE2)
- Effect of Intravenous Tranexamic Acid on Visual Clarity During Shoulder Arthroscopy in the Beach Chair Position (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic Acid (Intravenous) CI brief — competitive landscape report
- Tranexamic Acid (Intravenous) updates RSS · CI watch RSS
- The New England Baptist Hospital portfolio CI